logo
Hot nights stealing your sleep? Here's what scientists say could help

Hot nights stealing your sleep? Here's what scientists say could help

Malay Mail15-05-2025
PARIS, May 15 — Cool showers and less coffee or alcohol: sleep quality is being harmed by hotter temperatures caused by climate change, and scientists say we need to learn how to adapt.
The human brain is very sensitive to heat, with higher temperatures raising the body's central thermostat and activating stress systems.
Scientists are increasingly exploring mechanisms that can help the body adapt to rising temperatures affecting our sleep and leading to health complications.
'Rising temperatures induced by climate change and urbanisation pose a planetary threat to human sleep, and therefore health, performance, and wellbeing,' according to a 2024 review of scientific literature published in the journal Sleep Medicine.
Humans lost an average of 44 hours of sleep a year during the first two decades of the 21st century compared to earlier periods, according to a 2022 study published in the journal One Earth, which linked the data to rising temperatures.
The intensification of global warming could lead to an annual loss of 50 to 58 hours of sleep per person by 2099, according to research led by Kelton Minor, from the University of Copenhagen, based on data gathered from more than 47,000 individuals in 68 countries.
'Interventional studies and field experiments are now urgently needed to foster adaptation and safeguard the essential restorative role of sleep in a hotter world,' Minor and other authors of the paper said.
Neurons regulating temperature and sleep in the brain are highly interconnected, and lowering the body's internal thermostat is key to improving sleep quality.
Adapting to heat comes at a cost to the body, according to Fabien Sauvet, a researcher at Paris Cité University.
'We sweat more and faster, for example, but it requires additional hydration. And it has limits, so during heatwaves, the most important thing is to adapt our behaviour,' such as activities, schedules and clothing, Sauvet said.
But humans could 'tolerate higher temperatures than commonly thought', he added, pointing to several studies showing that good sleep quality can be achieved with a room temperature of up to 28°Celsius.
Challenging 'the false belief that the bedroom must be at 18°–20°C', he said that sleeping in light clothing such as a t-shirt and shorts, and with a simple sheet as well as good ventilation, could help dealing with a few more degrees.
'If we always sleep with air conditioning, we will never acclimatise,' he said.
Fight 'sleep enemies'
Armelle Rancillac, a neuroscientist at the Centre for Interdisciplinary Research in Biology, said anything beyond 28°C 'becomes much more complicated'.
An excessive lack of sleep is known to disrupt the body's recovery.
In the short term, this can lead to drowsiness, fatigue and a higher risk of accidents at the workplace or on the road.
In the long run, it can create a harmful sleep 'debt', impacting our metabolism and increasing the risk of weight gain, diabetes, cardiovascular diseases and even neurodegenerative diseases like Alzheimer's, Rancillac said.
A sleep deficit can also reduce stress resistance and have a negative impact on mental health.
To sleep better in a hotter environment, Rancillac stressed that there is a need to 'eliminate or at least pay attention to sleep enemies'.
Before bedtime, it is recommended to take a cool shower — but not an icy one — reduce stimulants like coffee, and limit alcohol, which facilitates falling asleep but slightly raises the internal body temperature.
Avoid hot tubs after a workout, opting instead for outdoor temperatures or a cold bath, said Sauvet.
Napping during the hottest hours of the day has also been proven to mitigate the impacts of a sleep deficit.
Short naps — '30 to 40 minutes, and before 2pm' — are ideal, so as not to interfere with a good night's sleep, according to the researcher. — AFP
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharma shares slump after Trump price threat
Pharma shares slump after Trump price threat

Free Malaysia Today

time14 hours ago

  • Free Malaysia Today

Pharma shares slump after Trump price threat

Donald Trump is targeting cutting US drug prices, which are among the world's highest. (AFP pic) PARIS : Shares in European pharmaceutical firms slumped on Friday following a threat by president Donald Trump to punish them if they don't lower prices for medicines in the US. Shares in Novo Nordisk, the Danish maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, saw shares drop 4.5% shortly after trading got under way in Copenhagen. Shares in Britain's AstraZeneca fell 2.8% in London, while Sanofi fell 1.1% in Paris. Meanwhile shares in Novartis shed 0.9% and Roche 1.0% after Trump announced Swiss goods will face a 39% tariff starting next week. Trump told major pharmaceutical firms Thursday to lower prices or face punishment, as he moved to give Americans relief from medicine costs much higher than elsewhere in the world. In letters to 17 drug companies published on his platform Truth Social, Trump said he wants the firms to work with his administration to institute a series of changes within 60 days. 'If you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,' Trump wrote without specifying what the consequences would entail. Trump is following up on an executive order he signed in May to address US drug prices that are among the highest in the world – more than three times what people in similarly developed countries pay, the White House said Thursday.

Justin Timberlake reveals ‘relentlessly debilitating' Lyme disease after world tour
Justin Timberlake reveals ‘relentlessly debilitating' Lyme disease after world tour

Malay Mail

time20 hours ago

  • Malay Mail

Justin Timberlake reveals ‘relentlessly debilitating' Lyme disease after world tour

LOS ANGELES, Aug 1 — Pop star Justin Timberlake told fans yesterday he has Lyme disease, a condition he described as 'relentlessly debilitating.' The 44-year-old former NSYNC frontman, whose world tour has just wrapped up, took to Instagram in reflective mood. 'This has been the most fun, emotional, gratifying, physically demanding, and, at times, grueling experience,' he said of a tour that was criticized by some fans as lackluster. 'Among other things, I've been battling some health issues, and was diagnosed with Lyme disease—which I don't say so you feel bad for me—but to shed some light on what I've been up against behind the scenes. 'Living with this can be relentlessly debilitating, both mentally and physically. When I first got the diagnosis I was shocked for sure. But, at least I could understand why I would be onstage and in a massive amount of nerve pain or just feeling crazy fatigue or sickness.' Lyme disease is caused by a bacteria often carried by ticks that live in woodlands throughout North America and Europe. Symptoms can include widespread pain, fatigue, and muscle weakness. In serious cases, patients could experience damage to the tissues, joints and immune system. The 'Can't Stop The Feeling' singer was in legal hot water last year after being arrested for drunk driving in a small town near New York. Timberlake, whose tumultuous relationship with Britney Spears was the inspiration for his 2002 smash 'Cry Me A River' later pleaded guilty to a lesser charge and was ordered to do community service. — AFP

AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030
AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030

Malay Mail

time4 days ago

  • Malay Mail

AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030

LONDON, July 29 — AstraZeneca Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the US, where it has invested US$50 billion (RM212 billion) to expand amid tariff threats from Washington. The performance is a boost for the UK's largest-listed company by market value as the wider sector braces for US tariffs on pharmaceutical imports and navigates pressure after President Donald Trump's order pushing for drugmakers to cut US prices to what other countries pay. AstraZeneca shares rose as much as 2.2 per cent by 0813 GMT. The drugmaker in April forecast only a limited impact from potential US tariffs, adding it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-US trade deal over the weekend will result in a 15 per cent tariff on pharmaceuticals from the region. The US accounted for more than 40 per cent of AstraZeneca's revenue in 2024. The company had prioritised the market — the world's largest, worth US$635 billion — even before Trump's return to office. AstraZeneca is betting on a wave of expected launches of 20 new medicines and its US expansion to reach US$80 billion in annual revenue by 2030 and offset generic competition. On Tuesday, it maintained its 2025 outlook and increased its interim dividend by 3 per cent. 'Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent,' CEO Pascal Soriot said. Cancer drugs outperform Sales of oncology drugs, constituting nearly half of AstraZeneca's revenue, were up 18 per cent at US$6.31 billion at constant currency rates in the quarter. Jefferies analysts said sales of drugs including Tagrisso, Lynparza, Calquence, Truqap and Imfinzi beat expectations. Total revenue for the three months ended June grew 11 per cent to US$14.46 billion, with double-digit growth in the US despite headwinds from changes in US Medicare price negotiations. Core earnings stood at US$2.17 per share. That compares with analysts' expectations of US$2.16, and US$14.15 billion in sales, according to a company-provided consensus. 'Operationally, this is the type of quarter we want to see,' Barclays analysts said. AstraZeneca is also hoping to move on from scandals in its second-biggest market, China, where it this year faced minor fines related to cancer drugs. It is also fighting patent challenges from an individual against Tagrisso. The company also delayed late-stage Avanzar trial data for a key lung cancer treatment to the first half of 2026. — Reuters

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store